Antithrombotic therapy immediately following stroke is important to minimise the risk of recurrence, but the optimum choice and number of drugs to use are unclear, and efficacy in preventing thrombosis needs to be weighed against bleeding risk. In The Lancet, the TARDIS investigators report findings from a randomised trial 1 that tested intensive antiplatelet therapy with three agents (aspirin, clopidogrel, and dipyridamole) against therapy based on current UK guidelines 2 (either clopidogrel, or aspirin plus dipyridamole) for 30 days in patients with transient ischaemic attack (TIA) or ischaemic stroke. Patients were randomly assigned within the first 48 h after symptom onset, and the investigators used an innovative primary endpoint at 90 days that captured both incidence and severity of recurrent stroke and TIA. However, after 3096 patients were randomly assigned (more than 70% of the target sample size of 4200 patients), the data monitoring committee recommended that the trial be stopped for futility (for the primary endpoint, adjusted common odds ratio [cOR] 0·90, 95% CI 0·67-1·20, p=0·47) and because of an increased risk of bleeding, particularly fatal bleeding, in the intensive therapy group (adjusted cOR 2·54, 95% CI 2·05-3·16, p<0·0001). If bleeding excess could be anticipated, how could triple therapy be futile in terms of efficacy when dual therapy seemed very efficacious in the CHANCE trial 3 (32% relative reduction in stroke compared with aspirin alone, and 49% in non-carriers of the CYP2C19 loss-of-function allele, who metabolise clopidogrel normally)? 4 First, TARDIS included not only patients with TIA (about a third of the study population), but also those with ischaemic stroke of various severities. About 11% of the study population had severe strokes (National Institutes of Health Stroke Scale NIHSS>6) and another 10% had undergone thrombolysis before randomisation. These patients have increased risk of bleeding complications, particularly intracerebral haemorrhage or haemorrhagic transformation, and indeed in the TARDIS trial there was a significant treatment-by-thrombolysis subgroup interaction for bleeding. Inclusion of severe strokes can only yield harm from an antithrombotic strategy, with no substantial benefit, because little or no remaining cerebral tissue in the hemisphere of the brain infarction can be preserved from a potential recurrent stroke; the choice to include these severe strokes in TARDIS might have contributed to the futility of its findings.
Second, 80 (40%) of the 198 recurrent events included in the primary endpoint were recurrent TIAs. Inclusion of an endpoint such as TIA is questionable because of the high risk of misdiagnosis (ie, TIA mimic), even by neurologists.
Third, 70% of patients were included 24-48 h after symptom onset, a time window with the highest risk of acute damage to the blood-brain barrier due to ischaemia, and in which a loading dose of clopidogrel and aspirin could also increase the risk of bleeding complications. It would be interesting to learn in further analysis of the TARDIS data whether haemorrhagic cerebral complications clustered during the first days of treatment in patients randomly assigned beyond 24 h.
Fourth, the duration of the triple therapy was the first 30 days after randomisation, rather than the entire 90 days of trial duration. Although this choice minimised exposure to bleeding complications, it might also have affected the efficacy outcome at 3 months and thereby futility. Conversely, most of the risk of recurrence in the CHANCE 3 and SOCRATES 5 trials and in the TIAregistry.org 6 occurred during the first 8-10 days, Learning from TARDIS: time for more focused trials in stroke prevention
